A variety of agents developed to inhibit BCR-signaling have shown significant clinical activity in CLL including the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide 3-kinase inhibitor, idelalisib.18,23,34 In light of their known clinical efficacy the effect of these agents on glucose uptake and enzyme induction was assessed. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.